• Breast Density Trial:  the Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial is intended to explore the effectiveness and cost of screening women ages 50 to 74 who have dense breast tissue, using mammography and MR compared with mammography alone. The trial will be supported by Bayer HealthCare's  Medical Care division (Radiology, June 23, 2015).                                             
  • LinkedIn 28 november 2019:  "In vrouwen met zeer dicht borstweefsel kan het toevoegen van MRI aan de screening, meer borstkanker en kanker in een vroeger stadium ontdekken. Dat zijn de eerste conclusies uit de grootschalige DENSE studie, geleid vanuit het UMC Utrecht. De resultaten van de DENSE trial zijn een belangrijke stap van 'one size fits all' borstkankeronderzoek naar “screening op maat”."  Lees verder:  Dens Trial
  • Lord Trial: behandeling DCIS graad 1:  A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-grade DCIS. This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, without any survival benefit. The LORD (LOw Risk DCIS) study is a randomized, international, multicenter, phase III non-inferiority trial, and aims to determine whether screen-detected low-grade DCIS can safely be managed by an active surveillance strategy or that the conventional treatment, being either WLE alone, WLE + RT, or mastectomy, and possibly HT, should remain the standard of care..